Active and progressive
A new duality of MS classification
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In this issue of Neurology®, Lublin and over 30 multiple sclerosis (MS) specialists from around the world propose a new consensus framework for MS classification.1 The increasing importance of MRI in clinical management and treatment trials, together with expanding treatment options and improved understanding of the pathophysiology of MS, motivated the present re-examination of MS phenotypic classifications and clinical course descriptions. The new schema supplants the one proposed by Lublin and Reingold2 in 1996 depicting 4 courses of MS that has been widely embraced in research and in clinical practice. The original 4 clinical subtypes were based on an international survey of MS clinicians, and utilized clinical information alone to describe relapsing-remitting, primary progressive, secondary progressive, and progressive-relapsing phenotypes. However, distinctions among the original 4 subtypes are imprecise and do not reflect current capabilities to target MS treatments based on integrated assessment of clinical and MRI data.
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 278
- © 2014 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors
Dr. Josep Dalmau and Dr. Mar Guasp
► Watch
Related Articles
Alert Me
Recommended articles
-
Views and Reviews
MRI features of benign multiple sclerosisToward a new definition of this disease phenotypeM. Rovaris, F. Barkhof, M. Calabrese et al.Neurology, May 11, 2009 -
Article
Gray matter damage predicts the accumulation of disability 13 years later in MSMassimo Filippi, Paolo Preziosa, Massimiliano Copetti et al.Neurology, October 11, 2013 -
Articles
A multicenter assessment of cervical cord atrophy among MS clinical phenotypesM.A. Rocca, M.A. Horsfield, S. Sala et al.Neurology, June 13, 2011 -
Article
MS, MRI, and the 2010 McDonald criteriaA Canadian expert commentaryDaniel Selchen, Virender Bhan, Gregg Blevins et al.Neurology, December 03, 2012